Physicians' Academy for Cardiovascular Education

Evaluating CV safety and potential for CV risk reduction with newer T2D agents

Sep. 5, 2015

A slide lecture program on glucose lowering agents on CV risk, like: DPP4 inhibitors, GLP1 agonists, SGLT2 inhibitors

Developed and provided by the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS), an initiative from Boehringer Ingelheim & Lilly and published as an educational service with permission at PACE-CME,
 

 

To download slides

Download PACE ACROSS T2D Module D_11Aug2015.pptx


To view slides clck on images